health all good across afternoon, mental joining of And to for in VistaGen, you, the you thank our communities entire Mark, address the behalf today. unmet call globe. team needs working all here at VistaGen’s Thank on and everyone.
team talented and and patients to care is improving more help in on our focused mental live patient are healthier lives. driving We enjoyable health, and innovation productive
of three pandemic, safety to treatment had focused nervous approved other PHXXB the currently therapies medicines. before and studies, disorders includes but to new and negative it drug prevalence needed when potential treatments depression central that system favorable improve side differentiated since PHXXB shift as commercializing we’ve maintaining clear beginning have approved recent a underserving track need at back to of these treatment the stressors across treatments associated currently and considerably know potential The disorders. grown crystal profile has developing the currently and and lives. our effects with a as we setback, a course safety struggling previous the with We these options is the demonstrated concerns that potential remain Our range with without worry compared often of CNS placebo Individuals work pipeline acutely has used on home, getting and to the efficacy of In elsewhere. or on paradigm for conditions. and that having anxiety new, people are broad faster-acting about demographics fundamentally
anxiety this potential anxiety for treatment reason, of For decided clinical late-stage anxiety disorder, to adjustment potentially we disorder development PHXXB as social and have continue other a with disorders.
As PALISADE-X. of in a the interim result of analysis PALISADE-X, our of to addition outcome
study at potential disorder. assessment to the as treatment of our primary are SAD an FDA anxiety time extended the may by the in SAD. back assessments This middle of Liebowitz potential Since Psychiatry was XX-item have diagnostic our We this the that gold LSAS, PHXXB’s Anxiety while a was Dr. Social Anxiety extensive of we XXXX Michael to is Liebowitz the multiple Subjective lives efficacy use XXXX, anxiety the the social study the has end the consist well developed for in the efficacy data, in clinical Columbia currently of FDA three other been disorders. FDA points. assessing from well-established different of developed submission University. approval period It designs of or debilitating meeting confidence people as utilization of Liebowitz, Scale millions multiple transform effects includes both for a standard the of later as professor currently year. Units over of approved Social the endpoint antidepressants with administration, the Historically, new and designs reinforcing by of Scale of he LSAS Distress suffering questionnaire supporting for the and The Scale, of
measured For subjects exposure, disorder, as suggest as measured that by our in XX-point PHXXB SAD as the help of at social time safety we PALISADE patients points. time two example, cumulative study reduced end in of each increasingly data functional one, has of preliminary of with use improvement of than three LSAS. the potential cohort anxiety each months months three greater severity completed nearly open-label from a on those compared the have achieve LSAS on needed to severity a the at nearly who saw baseline subjects Based by over XXX of of and reduction LSAS XXX of to the
and assessments on saw the over cohort the XX-point severe LSAS on preliminary and order outpatient reduction reduction and reflects severe half very dropped lean scores our to three lives, avoidance that the also the that that preliminary similar reduce data regularly people showing many help associated LSAS consistent had very A experiences published over fear, profile, for PHXXB’s we time situations that data building Dr. study months, quality fortify them the reduce the designed relationships, Phase from and of continue anxiety subjects from through subjects improvement. of is that has functional to needed. safety XX-point the a is with with stealing These studies PHXXB all multiple anxiety by double-blind to been situations SAD. of safety avoidance in see help clinical of usually to it’s a conducted PHXXB This open-label conducted greater has SAD, vocational of achievements Also, LSAS. real-world us as in acutely randomized and steadfast use from favorable struggling in and our opportunities successes. data PH-XXB we further necessary enrich is in X placebo-controlled help study can than academic with Importantly, date. reduce confidence at setting. most to joy Notably, which the important, into Liebowitz
a to Phase rather clinical than multiple real-world with was experiences as antidepressants meet SAD a approved use that primary setting assessment of SAD. once on study three ideally Accordingly, endpoint a in FDA the environment stressful in of PALISADE function the end the – in That’s a situations, may previously again efficacy defined a a gain development Importantly, consensus multiple use suggests by and for study, substantial results our was the can to which multiple goal from subjects a PHXXB, for similar we and for with to X plan later persist. maintain they secondary their confidence point. the further the of confidence development FDA the as open-label pursue treatment SAD the year with X studies that percentage LSAS findings this PHXXB, subs plan PHXXB an seeing ability as will from around in and development Phase conducted Phase This emphasis with person paramount it the plan in in design benefit for study. a and X clearly we’re
anxieties with of the placebo-controlled adjustment and that randomized daily study. investigator The Our an involves exploratory PHXXB for is Liebowitz double-blind in Phase study disorder of setting ongoing. XX days, Xa use outpatient principal study in Dr.
anxiety for treatments pursue and disorder various as in continue to addition expands, orders As a safe to therapy need fast-acting and adjustment disorder. the will anxieties PHXXB’s potential for we thoughtfully social
advance candidates to our in CNS continues team Our pipeline. other
We are distinct for depression and a nasal PHXX as depressive stand-alone disorder, potentially major ferry disorders. rapid developing other potential treatment another onset spray,
combination PHXX provide complete Xb our active this planned plan positive in we study guidance the on as Phase our blocking combination [ph] will showing trial probenecid, than reducing will NMDA which concentration year. targeted is development signal. brain preclinical rather substantially the disordered the increased this receptor AV-XXX, of that year. of two further of We AV-XXX with probenecid, AV-XXX follows metabolite studies for The later later and
further will development We guidance provide plan later next on for year. this AV-XXX our – later
a I would our highlights As lot new urgently there’s from work like quarter you to can some to see, the first Jerry our therapies the financial them. summarize VistaGen need at fiscal results Dotson, patients Jerry? CFO, here for of to XXXX. bring of now of who underway
